Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDNA Stock Forecast 2026-2027
$20.32
Current Price
$1.07B
Market Cap
Buy 3
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to CDNA Price Targets
+28.0%
To High Target of $26.00
+3.3%
To Median Target of $21.00
-11.4%
To Low Target of $18.00
CDNA Price Momentum
+18.0%
1 Week Change
+2.1%
1 Month Change
-10.5%
1 Year Change
+7.9%
Year-to-Date Change
-21.7%
From 52W High of $25.95
+85.4%
From 52W Low of $10.96
📊 TOP ANALYST CALLS
Did CDNA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CareDx is one of their latest high-conviction picks.
Latest CDNA Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, CDNA has a neutral consensus with a median price target of $21.00 (ranging from $18.00 to $26.00). The overall analyst rating is Buy (7.5/10). Currently trading at $20.32, the median forecast implies a 3.3% upside. This outlook is supported by 3 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Connor Chamberlain at Craig-Hallum, projecting a 28.0% upside. Conversely, the most conservative target is provided by Brandon Couillard at Wells Fargo, suggesting a 11.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDNA Analyst Ratings
3
Buy
5
Hold
0
Sell
CDNA Price Target Range
Low
$18.00
Average
$21.00
High
$26.00
Current: $20.32
Latest CDNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 15, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $18.00 |
| Nov 6, 2025 | BTIG | Mark Massaro | Buy | Maintains | $25.00 |
| Sep 23, 2025 | BTIG | Mark Massaro | Buy | Reiterates | $22.00 |
| Sep 12, 2025 | BTIG | Mark Massaro | Buy | Reiterates | $22.00 |
| Aug 26, 2025 | William Blair | Andrew Brackmann | Market Perform | Initiates | $N/A |
| Aug 8, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $14.00 |
| Jul 18, 2025 | Craig-Hallum | Connor Chamberlain | Buy | Maintains | $26.00 |
| May 5, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $25.00 |
| May 5, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $40.00 |
| Apr 17, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $26.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Maintains | $25.00 |
| Feb 27, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $40.00 |
| Jan 15, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Upgrade | $24.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $26.00 |
| Nov 5, 2024 | BTIG | Sung Ji Nam | Buy | Maintains | $35.00 |
| Oct 22, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $N/A |
| Oct 16, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $35.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Underweight | Initiates | $28.00 |
| Aug 19, 2024 | BTIG | Sung Ji Nam | Buy | Upgrade | $40.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $N/A |
CareDx Inc. (CDNA) Competitors
The following stocks are similar to CareDx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CareDx Inc. (CDNA) Financial Data
CareDx Inc. has a market capitalization of $1.07B with a P/E ratio of 15.8x. The company generates $358.00M in trailing twelve-month revenue with a 19.7% profit margin.
Revenue growth is +20.7% quarter-over-quarter, while maintaining an operating margin of -0.2% and return on equity of +24.1%.
Valuation Metrics
Market Cap
$1.07B
Enterprise Value
$891.40M
P/E Ratio
15.8x
PEG Ratio
-0.1x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
+20.7%
Gross Margin
+69.4%
Operating Margin
-0.2%
Net Margin
+19.7%
EPS Growth
+20.7%
Financial Health
Cash/Price Ratio
+18.6%
Current Ratio
3.0x
Debt/Equity
8.9x
ROE
+24.1%
ROA
-4.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CareDx Inc. (CDNA) Business Model
About CareDx Inc.
What They Do
Specializes in transplant care diagnostics.
Business Model
CareDx generates revenue by providing innovative diagnostic solutions and services for organ transplant patients. Their key products, such as the AlloSure and AlloMap tests, utilize genomic technology to monitor the health of organ transplants and assess the risk of rejection, which are critical for patient management in transplant centers.
Additional Information
The company is positioned at the intersection of biotechnology and healthcare, contributing to improved patient care through non-invasive diagnostics. CareDx's technology not only enhances patient outcomes but also aids in cost reduction and the advancement of precision medicine globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
644
CEO
Mr. John Walter Hanna Jr.
Country
United States
IPO Year
2014
Website
caredx.comCareDx Inc. (CDNA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
Jan 13, 2026
By Zacks Equity Research
Analyst Blog
Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now?
CI looks worth holding as Evernorth growth, expanding pharmacy services, cheap valuation and shareholder returns support its long-term outlook.
Jan 06, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
CareDx, Inc. reported preliminary Q4 2025 revenue of approximately $108 million, reflecting a 25% year-over-year increase.
Why It Matters
CareDx's 25% revenue growth indicates strong demand for its transplant solutions, potentially boosting investor confidence and stock value. Positive financial performance can attract more investment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CareDx, Inc. announced a collaboration with 10x Genomics to launch ImmuneScape™, a multiomics research initiative aimed at advancing transplant patient care.
Why It Matters
CareDx's collaboration with 10x Genomics enhances its innovation in precision medicine for transplant patients, potentially boosting growth and market competitiveness, which may attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CareDx, Inc. (Nasdaq: CDNA) announced the grant of restricted stock units to 39 new employees as an employment inducement on December 19, 2025.
Why It Matters
CareDx's issuance of RSUs to new employees signals confidence in growth and employee retention, potentially enhancing productivity and long-term company value, influencing investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CareDx, Inc. announced a proposed settlement of shareholder derivative actions pending in the U.S. District Court for the Northern District of California.
Why It Matters
CareDx's proposed settlement of derivative actions may affect its legal liabilities and governance, impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Wall Street analysts project a 28% upside for CareDx (CDNA), supported by positive earnings estimate revisions, despite questions about the reliability of price targets.
Why It Matters
A 28% potential upside in CareDx's price targets and positive earnings revisions signal bullish sentiment, suggesting a likely increase in stock value, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CareDx, Inc. (Nasdaq: CDNA) published a manuscript from its Surveillance HeartCare Outcomes Registry in the Journal of Heart and Lung Transplantation, focusing on multimodal molecular testing.
Why It Matters
CareDx's new research publication may enhance credibility and visibility in the transplant healthcare market, potentially driving stock performance and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CDNA Stock
What is CareDx Inc.'s (CDNA) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, CareDx Inc. (CDNA) has a median price target of $21.00. The highest price target is $26.00 and the lowest is $18.00.
Is CDNA stock a good investment in 2026?
According to current analyst ratings, CDNA has 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDNA stock?
Wall Street analysts predict CDNA stock could reach $21.00 in the next 12 months. This represents a 3.3% increase from the current price of $20.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CareDx Inc.'s business model?
CareDx generates revenue by providing innovative diagnostic solutions and services for organ transplant patients. Their key products, such as the AlloSure and AlloMap tests, utilize genomic technology to monitor the health of organ transplants and assess the risk of rejection, which are critical for patient management in transplant centers.
What is the highest forecasted price for CDNA CareDx Inc.?
The highest price target for CDNA is $26.00 from Connor Chamberlain at Craig-Hallum, which represents a 28.0% increase from the current price of $20.32.
What is the lowest forecasted price for CDNA CareDx Inc.?
The lowest price target for CDNA is $18.00 from Brandon Couillard at Wells Fargo, which represents a -11.4% decrease from the current price of $20.32.
What is the overall CDNA consensus from analysts for CareDx Inc.?
The overall analyst consensus for CDNA is neutral. Out of 13 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are CDNA stock price projections?
Stock price projections, including those for CareDx Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 2:31 AM UTC